Our first-in-class, in-development tests are next generation of liquid biopsy tests based on exosomes. Single sampling, on-site deployment, and no NGS make these tests one of the first globally. Two assays from our core exosome discovery technology first ensures high yield and enrichment of exosomes from biofluid sample followed by instant purification of exosomes into clinical grade within 30 minutes. These biomarkers rich, high purity exosomes are then used in downstream analysis (PCR/ELISA) to identify multiple classes of tumour specific molecules (DNA mutations, RNA, proteins) in parallel. We bring the next Frontiers in liquid Biopsy for cancer with high precision & scalability. We are democratizing access to liquid Biopsy at mass level with our upcoming tests.